Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Mathias Due Buron, Rigshospitalet
  • ,
  • Thor Ameri Chalmer, Rigshospitalet
  • ,
  • Finn Sellebjerg, Rigshospitalet
  • ,
  • Ismael Barzinji, Aalborg Universitet
  • ,
  • Jeppe Romme Christensen, Rigshospitalet
  • ,
  • Mette Kirstine Christensen, Aarhus Universitet
  • ,
  • Victoria Hansen, Aalborg Universitet
  • ,
  • Zsolt Illes, Odense University Hospital
  • ,
  • Henrik Boye Jensen, Lillebaelt Hospital
  • ,
  • Matthias Kant, Hospital of Southern Jutland, Sønderborg
  • ,
  • Viktoria Papp, Odense University Hospital
  • ,
  • Thor Petersen
  • Peter Vestergaard Rasmussen
  • Jakob Schäfer, Aalborg Universitet
  • ,
  • Ásta Theódórsdóttir, Odense University Hospital
  • ,
  • Arkadiusz Weglewski, Herlev Hospital, Herlev, Denmark.
  • ,
  • Per Soelberg Sorensen, Rigshospitalet
  • ,
  • Melinda Magyari, Rigshospitalet

OBJECTIVE: To determine the effectiveness of high-efficacy disease-modifying therapies (heDMTs) vs medium-efficacy disease-modifying therapies (meDMT) as the first treatment choice in treatment-naive patients with multiple sclerosis (MS) on disability worsening and relapses. We assessed this using a nationwide population-based MS registry. METHODS: We identified all patients starting a heDMT as first-time treatment from the Danish Multiple Sclerosis Registry and compared treatment outcomes with a propensity score matched sample of patients starting meDMT. RESULTS: We included 388 patients in the study: 194 starting initial therapy with heDMT matched to 194 patients starting meDMT. At 4 years of follow-up, the probabilities of a 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening were 16.7% (95% confidence interval [CI] 10.4%-23.0%) and 30.1% (95% CI 23.1%-37.1%) for heDMT and meDMT initiators, respectively (hazard ratio [HR] 0.53, 95% CI 0.33-0.83, p = 0.006). Patients initiating heDMT also had a lower probability of a first relapse (HR 0.50, 95% CI 0.37-0.67). Results were similar after pairwise censoring and in subgroups with high baseline activity, diagnosis after 2006, or information on baseline T2 lesion load. CONCLUSION: We found a lower probability of 6-month confirmed EDSS score worsening and lower probability of a first relapse in patients starting a heDMT as first therapy, compared to a matched sample starting meDMT. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with MS, starting heDMT lowers the risk of EDSS worsening and relapses compared to starting meDMT.

OriginalsprogEngelsk
TidsskriftNeurology
Vol/bind95
Nummer8
Sider (fra-til)e1041-e1051
ISSN0028-3878
DOI
StatusUdgivet - aug. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 196008249